Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas

In the second quarter, nine of the world's top 25 drugmakers accomplished double-digit revenue increases, led again by Eli Lilly, which charted a 48% sales gain. The revenue boom was even more pronounced when comparing figures between the first and second quarters. Of the top 25 drugmakers, more than half realized double-digit sequential gains and only one saw a decline.